Survey on the Influence of Living Environment Factors on Diagnosis of Idiopathic Pulmonary Fibrosis in Foshan
DOI:
https://doi.org/10.47611/jsrhs.v11i2.2633Keywords:
Idiopathic pulmonary fibrosis, Living environment factors, Diagnostic difficulty, Ridge regressionAbstract
Purpose of the study: (a) investigate the relationship between the time and diagnosis of IPF and its influencing factors, (b) provide information from patients' real-life diagnostic experiences for the development of more rational diagnostic pathways and the introduction of more treatment options and technologies, and (c) improve the publics’ awareness of IPF and promote the prevention of IPF.
Methods of investigation: A questionnaire was designed to survey 37 patients with IPF in January 2022, including general information questionnaires and age, sex, time for diagnosis, etc. Ridge regression analysis was used to explore the factors influencing the length and difficulty of IPF diagnosis. In addition, 11 respiratory physicians were interviewed by online interview about the difficulty of IPF diagnosis, treatment options, and patient prognosis.
Results: The stress caused by the lack of formal diagnosis (B=0.617, p<0.001), the high cost of the diagnosis process (B=0.509, p<0.001), and the number of misdiagnoses or missed diagnoses (B=0.177, p<0.005) were significantly related to the length and difficulty of the IPF diagnosis (p<0.05).
Conclusions: The findings highlight the need for new appropriate, convenient, and economical diagnostic procedures to be developed and designed. Simultaneously, professionals should strengthen the dissemination of disease understanding among the susceptible population, improve understanding and attention to the patients' condition, and conduct more lectures on the basics of avoiding IPF to strengthen the knowledge, which can effectively improve the mental quality of the susceptible population, in conjunction with the advice given by the doctors in the interviews.
Downloads
References or Bibliography
Azuma, A., Nukiwa, T., Tsuboi, E., Suga, M., Abe, S., Nakata, K., Taguchi, Y., Nagai, S., Itoh, H., Ohi, M., Sato, A., & Kudoh, S. (2005). Double-blind, placebo-controlled trial of pirfenidone in patients with idiopathic pulmonary fibrosis. Am J Respir Crit Care Med, 171(9), 1040-1047. https://doi.org/10.1164/rccm.200404-571OC
Fell, C. D., Martinez, F. J., Liu, L. X., Murray, S., Han, M. K., Kazerooni, E. A., Gross, B. H., Myers, J., Travis, W. D., Colby, T. V., Toews, G. B., & Flaherty, K. R. (2010). Clinical predictors of a diagnosis of idiopathic pulmonary fibrosis. Am J Respir Crit Care Med, 181(8), 832-837. https://doi.org/10.1164/rccm.200906-0959OC
Fingerlin, T. E., Murphy, E., Zhang, W., Peljto, A. L., Brown, K. K., Steele, M. P., Loyd, J. E., Cosgrove, G. P., Lynch, D., Groshong, S., Collard, H. R., Wolters, P. J., Bradford, W. Z., Kossen, K., Seiwert, S. D., du Bois, R. M., Garcia, C. K., Devine, M. S., Gudmundsson, G., Isaksson, H. J., Kaminski, N., Zhang, Y., Gibson, K. F., Lancaster, L. H., Cogan, J. D., Mason, W. R., Maher, T. M., Molyneaux, P. L., Wells, A. U., Moffatt, M. F., Selman, M., Pardo, A., Kim, D. S., Crapo, J. D., Make, B. J., Regan, E. A., Walek, D. S., Daniel, J. J., Kamatani, Y., Zelenika, D., Smith, K., McKean, D., Pedersen, B. S., Talbert, J., Kidd, R. N., Markin, C. R., Beckman, K. B., Lathrop, M., Schwarz, M. I., & Schwartz, D. A. (2013). Genome-wide association study identifies multiple susceptibility loci for pulmonary fibrosis. Nat Genet, 45(6), 613-620. https://doi.org/10.1038/ng.2609
Jain, N., & Lethagen, S. (2020). RE: Reyes A, Revil C, Niggli M, et al. Efficacy of emicizumab prophylaxis versus factor VIII prophylaxis for treatment of hemophilia A without inhibitors: network meta-analysis and sub-group analyses of the intra-patient comparison of the HAVEN 3 trial. Curr Med Res Opin. 2019;35(12):2079-2087. Curr Med Res Opin, 36(7), 1125-1127. https://doi.org/10.1080/03007995.2020.1744549
KENT A. GRIFFITH, D. L. S., ERIN M. SIEGEL, TERI A. MANOLIO, HORACE W. BONEKAT,, & ENRIGHT, a. P. L. (1999). Predictors of Loss of Lung Function in the Elderly. https://doi.org/10.1164/ajrccm.163.1.9906089
The Cardiovascular Health Study. Respiratory Sciences Center, University of Arizona, Tucson, Arizona; National Heart, Lung, and Blood Institute, Bethesda, Maryland; and Universityof California at Davis Medical Center, Davis, California. https://doi.org/https://doi.org/10.1164/ajrccm.163.1.9906089
Kim, H. J., Perlman, D., & Tomic, R. (2015). Natural history of idiopathic pulmonary fibrosis. Respir Med, 109(6), 661-670. https://doi.org/10.1016/j.rmed.2015.02.002
Lamas, D. J., Kawut, S. M., Bagiella, E., Philip, N., Arcasoy, S. M., & Lederer, D. J. (2011). Delayed access and survival in idiopathic pulmonary fibrosis: a cohort study. Am J Respir Crit Care Med, 184(7), 842-847. https://doi.org/10.1164/rccm.201104-0668OC
Noth, I., Anstrom, K. J., Calvert, S. B., de Andrade, J., Flaherty, K. R., Glazer, C., Kaner, R. J., Olman, M. A., & Idiopathic Pulmonary Fibrosis Clinical Research, N. (2012). A placebo-controlled randomized trial of warfarin in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med, 186(1), 88-95. https://doi.org/10.1164/rccm.201202-0314OC
Orens, J. B., Kazerooni, E. A., Martinez, F. J., Curtis, J. L., Gross, B. H., Flint, A., & Lynch, J. P., 3rd. (1995). The sensitivity of high-resolution CT in detecting idiopathic pulmonary fibrosis proved by open lung biopsy. A prospective study. Chest, 108(1), 109-115. https://doi.org/10.1378/chest.108.1.109
Qualtrics. Survey bias types that researchers need to know about. https://www.qualtrics.com/uk/experience-management/research/survey-bias/
Raghu, G., Chen, S.-Y., Yeh, W.-S., Maroni, B., Li, Q., Lee, Y.-C., & Collard, H. R. (2014). Idiopathic pulmonary fibrosis in US Medicare beneficiaries aged 65 years and older: incidence, prevalence, and survival, 2001–11. The Lancet Respiratory Medicine, 2(7), 566-572. https://doi.org/10.1016/s2213-2600(14)70101-8
Raghu, G., Collard, H. R., Egan, J. J., Martinez, F. J., Behr, J., Brown, K. K., Colby, T. V., Cordier, J. F., Flaherty, K. R., Lasky, J. A., Lynch, D. A., Ryu, J. H., Swigris, J. J., Wells, A. U., Ancochea, J., Bouros, D., Carvalho, C., Costabel, U., Ebina, M., Hansell, D. M., Johkoh, T., Kim, D. S., King, T. E., Jr., Kondoh, Y., Myers, J., Muller, N. L., Nicholson, A. G., Richeldi, L., Selman, M., Dudden, R. F., Griss, B. S., Protzko, S. L., Schunemann, H. J., & Fibrosis, A. E. J. A. C. o. I. P. (2011). An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management. Am J Respir Crit Care Med, 183(6), 788-824. https://doi.org/10.1164/rccm.2009-040GL
Richeldi, L., Collard, H. R., & Jones, M. G. (2017). Idiopathic pulmonary fibrosis. The Lancet, 389(10082), 1941-1952. https://doi.org/10.1016/s0140-6736(17)30866-8
Richeldi, L., du Bois, R. M., Raghu, G., Azuma, A., Brown, K. K., Costabel, U., Cottin, V., Flaherty, K. R., Hansell, D. M., Inoue, Y., Kim, D. S., Kolb, M., Nicholson, A. G., Noble, P. W., Selman, M., Taniguchi, H., Brun, M., Le Maulf, F., Girard, M., Stowasser, S., Schlenker-Herceg, R., Disse, B., Collard, H. R., & Investigators, I. T. (2014). Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis. N Engl J Med, 370(22), 2071-2082. https://doi.org/10.1056/NEJMoa1402584
Sarniak, R. (2015). 9 types of research bias and how to avoid them. https://www.quirks.com/articles/9-types-of-research-bias-and-how-to-avoid-them
Somogyi, V., Chaudhuri, N., Torrisi, S. E., Kahn, N., Muller, V., & Kreuter, M. (2019). The therapy of idiopathic pulmonary fibrosis: what is next? Eur Respir Rev, 28(153). https://doi.org/10.1183/16000617.0021-2019
Travis, W. D., Costabel, U., Hansell, D. M., King, T. E., Jr., Lynch, D. A., Nicholson, A. G., Ryerson, C. J., Ryu, J. H., Selman, M., Wells, A. U., Behr, J., Bouros, D., Brown, K. K., Colby, T. V., Collard, H. R., Cordeiro, C. R., Cottin, V., Crestani, B., Drent, M., Dudden, R. F., Egan, J., Flaherty, K., Hogaboam, C., Inoue, Y., Johkoh, T., Kim, D. S., Kitaichi, M., Loyd, J., Martinez, F. J., Myers, J., Protzko, S., Raghu, G., Richeldi, L., Sverzellati, N., Swigris, J., Valeyre, D., & Pneumonias, A. E. C. o. I. I. (2013). An official American Thoracic Society/European Respiratory Society statement: Update of the international multidisciplinary classification of the idiopathic interstitial pneumonias. Am J Respir Crit Care Med, 188(6), 733-748. https://doi.org/10.1164/rccm.201308-1483ST
Wu, Q., Zhou, Y., Feng, F. C., & Zhou, X. M. (2019). Effectiveness and Safety of Chinese Medicine for Idiopathic Pulmonary Fibrosis: A Systematic Review and Meta-Analysis. Chin J Integr Med, 25(10), 778-784. https://doi.org/10.1007/s11655-017-2429-5
Published
How to Cite
Issue
Section
Copyright (c) 2022 Yadan Huang; Zhenpeng Liu
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
Copyright holder(s) granted JSR a perpetual, non-exclusive license to distriute & display this article.
